Yael Hayon - 07 Sep 2022 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
VP, Research & Development
Signature
/s/ Eyal Rubin, POA
Issuer symbol
PLX
Transactions as of
07 Sep 2022
Net transactions value
$0
Form type
4
Filing time
09 Sep 2022, 17:03:38 UTC
Next filing
17 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLX Stock Options (Right to Buy) Award $0 +250,000 $0.000000 250,000 07 Sep 2022 Common Stock 250,000 $1.03 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
F2 Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030.